ArticleScientific reports2025
Design of a multi-epitope vaccine candidate against Vibrio cholerae.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Immunopharmacological and structural design of a polyprotein based multi epitope vaccine against Powassan virus.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Rpf-Toxo: A Preliminary Computationally Designed Dense Granule Antigen-Based Multi-Epitope Vaccine Against Toxoplasma gondii.Veterinary medicine and science · 2026Article
- Toward a Vaccine Against Multidrug-Resistant Elizabethkingia anophelis: Comprehensive Immunoinformatics-Based Design of a Multi-Epitope Vaccine and mRNA Construct.Probiotics and antimicrobial proteins · 2026Article
- Proteome conserved multi-epitope-based vaccine construct against Nipah virus.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Designing of a conserved subunit multiepitope vaccine candidate against Francisella tularensis Schu S4 using immunoinformatics.Scientific reports · 2026Article
- Pharmaceutical design of mRNA vaccines for endemic infectious diseases: integrating antigen discovery with platform engineering.Clinical and experimental vaccine research · 2026Review
- Designing a novel multiepitope vaccine candidate against Treponema pallidum via adhesins using reverse vaccinology.Scientific reports · 2026Article
- Phylogeny-guided multi-epitope vaccine design targeting conserved and divergent regions of Brucella OMP2, OMP25, and OMP31: an immunoinformatics study.BMC immunology · 2026Article
- Immunoinformatics-based design and evaluation of a multi-epitope vaccine against Vibrio fluvialis.Scientific reports · 2026Article
- Immunoinformatics and molecular modeling approaches to design a multi-epitope vaccine against Tibrovirus Congo.Open medicine (Warsaw, Poland) · 2026Article
- In silico design of a multi-epitope vaccine against the triple negative breast cancer.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholera is an acute, highly contagious diarrheal disease caused by the gram-negative bacterium Vibrio cholerae, typically contracted through contaminated water or food. Without timely treatment, cholera can lead to severe dehydration and death. The COVID-19 pandemic has underscored the critical importance of vaccine development, emphasizing the need for effective vaccines against various diseases. Despite the complexity and high costs associated with vaccine design, advancements in bioinformatics and immunoinformatics offer computational methods that accelerate research and provide valuable immunological insights. In this study, we utilized computational approaches to design a multi-epitope vaccine against V. cholerae. We started with the V. cholerae genome and identified 19,155 possible antigens, all of which underwent various computational filters to determine the best candidates. Finally, we identified the two best antigens for vaccine development. One of the key achievement of our study was the identification of these antigens, as they successfully passed all computational tests among all possible antigens. This finding may open new immunological pathways in designing vaccines against V. cholerae. These antigens served as the foundation for identifying B-cell, MHC I, and MHC II epitopes. Using linkers and an adjuvant, these epitopes formed the core components of our vaccine. The designed vaccine underwent multiple evaluations and successfully passed all assessments, demonstrating its potential efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.